Relapsed or Refractory Myelodysplastic Syndromes (R/R MDS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032


 Myelodysplastic syndromes (MDS) are characterized by ineffective hematopoiesis leading to reduced blood cell production and clonal instability, which carries a potential risk of progressing to acute myeloid leukemia (AML). Individuals affected by MDS experience a significant burden of symptoms and are also susceptible to mortality due to complications arising from reduced blood cell counts and the development of AML. The etiology of MDS is currently understood in only 15% of cases. Inherited susceptibility to MDS is observed in approximately one-third of pediatric MDS cases, encompassing conditions such as Down syndrome, Fanconi anemia, and neurofibromatosis. While less common in adults, an inherited predisposition should be considered when MDS arises in young adults or families with a history of MDS, AML, or aplastic anemia. Familial instances of MDS have been associated with point mutations in various genes, including DDX41, GATA2, RUNX1, ANKRD26, ETV6, and genes related to the telomerase complex (TERC and TERT). Environmental factors contributing to MDS include prior exposure to chemotherapeutic agents, particularly alkylating agents, and purine analogs, as well as radiotherapy or ionizing radiation and tobacco use. Noteworthy occupational factors encompass benzene and its derivatives, with a heightened incidence of MDS among agricultural and industrial workers. Diagnosing MDS involves assessing blood and bone marrow samples, revealing reduced blood cell counts and typically hypercellular (though sometimes hypocellular) marrow displaying dysplastic features, possibly accompanied by an excess of immature cells (blasts). Patients grappling with relapsed or refractory higher-risk myelodysplastic syndromes have a discouraging median overall survival ranging from 4.3 to 5.6 months, along with a 28% one-year survival probability following the failure of the two endorsed hypomethylating agents, namely azacitidine (Aza) and decitabine (Dec).

 

·       The prevalence of myelodysplastic syndrome in the United States population is approximately 3.4 cases per 100,000 individuals.

Thelansis’s “Relapsed or Refractory Myelodysplastic Syndromes (R/R MDS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Relapsed or Refractory Myelodysplastic Syndromes (R/R MDS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Relapsed or Refractory Myelodysplastic Syndromes (R/R MDS) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Relapsed or Refractory Myelodysplastic Syndromes (R/R MDS) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Relapsed or Refractory Myelodysplastic Syndromes (R/R MDS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Comments

Post a Comment

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
  Acne vulgaris, a prevalent pilosebaceous unit inflammatory skin disorder, follows a persistent course. Typically presenting as papules, pustules, or nodules, it primarily occurs on the face but can also impact the upper arms, trunk, and back. The development of acne results from the sebaceous glands' heightened sensitivity to normal androgen levels, aggravated by Cutibacterium acnes (formerly known as Propionibacterium acnes), a bacterial species that triggers inflammation. The pathogenesis of acne vulgaris involves a complex interplay of factors such as the activation of sebaceous glands by androgens, imbalances in the pilosebaceous follicle microbiome, and cellular immune responses. Genetic predisposition and dietary influences also contribute to the condition's onset and progression. The initial stage is the micro-comedo, a small plug primarily composed of corneocytes in the lower follicular infundibulum. Microcomedones evolve into various acne lesions, including closed co...
Read more

Metabolic Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Metabolic syndrome refers to a clustering of multiple disorders that collectively increase an individual's susceptibility to atherosclerotic cardiovascular disease, insulin resistance, diabetes mellitus, as well as vascular and neurological complications such as cerebrovascular accidents. The underlying causes of metabolic syndrome typically include excess weight, obesity, a sedentary lifestyle, and genetic predisposition. This syndrome exerts detrimental effects on various body systems. Insulin resistance, a key component of metabolic syndrome, leads to microvascular damage, increasing the risk of endothelial dysfunction, vascular resistance, hypertension, and inflammation of vessel walls. Bariatric surgery is recognized as the most effective standalone therapy for metabolic syndrome. However, patients undergoing this procedure require long-term follow-up to mitigate potential surgical, nutritional, and psychiatric complications. Thelansis’s “Metabolic Syndrome Market Outl...
Read more

Type 1 Diabetes Mellitus (T1D) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Type 1 Diabetes Mellitus (T1D) is characterized as an autoimmune disorder resulting in the autoimmune destruction of insulin-producing pancreatic beta cells. This condition necessitates life-long insulin replacement, administered through multiple daily insulin injections, insulin pump therapy, or an automated insulin delivery system. The absence of insulin can lead to the development of Diabetic Ketoacidosis (DKA), a life-threatening condition. The most common symptoms associated with this disease are polyuria and polydipsia. Effective management of T1D involves: Multiple daily insulin injections Insulin pump therapy An automated insulin delivery system in conjunction with glucose monitoring Continuous Glucose Monitoring (CGM) is the preferred method. However, all individuals with T1D should be capable of performing Blood Glucose Monitoring (BGM) via capillary blood if CGM is not available. Acute complications of diabetes primarily include hypo...
Read more